Pharmaceutical companies will be required to disclose drug prices in television commercials in the United States under a new rule finalized by the Department of Health and Human Services.
According to Bloomberg, the rule will apply to medicines if the price for a month’s supply (or the usual course of therapy) before rebates and discounts is more than $35. The rule is part of an effort to help lower drug prices.
According to Health and Human Services Secretary Alex Azar, “Patients who are struggling with high drug costs are in that position because of the high list prices that drug companies set. Making those prices more transparent is a significant step in President Trump’s efforts to reform our prescription drug markets and put patients in charge of their own health care.”
The rule will go into effect 60 days after it’s published. Manufacturers Johnson & Johnson and Eli Lilly have already started including pricing information for ads for Xarelto (rivaroxaban) and Trulicity (dulaglutide), respectively.
Source URL: https://www.diabetesselfmanagement.com/blog/drug-prices-to-be-required-in-television-ads/
Diane Fennell: Diane Fennell has been an editor at Diabetes Self-Management magazine since 2003. She is currently the Editorial Director. (Diane Fennell is not a medical professional.)
Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.
Copyright ©2020 Diabetes Self-Management unless otherwise noted.